Comment from Vitalant

Summary: Vitalant, a nonprofit blood and biotherapies healthcare organization, supports the FDA's goal of creating a structured framework for responding to Form 483 observations. However, they argue that the draft guidance is overly prescriptive for routine observations and recommend that the FDA clarify that many of the suggested response elements should be optional and risk-based.